|
Trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastroesophageal junction cancer (mGEJC): Subgroup analysis from TAGS. |
|
|
|
|
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; SERVIER |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Lilly; MSD; Roche/Genentech |
Travel, Accommodations, Expenses - Amgen; Lilly; Merck Serono; Roche/Genentech |
|
|
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical |
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Lilly; MSD; Ono Pharmaceutical; Pfizer; Takeda |
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Mediscience Planning (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst) |
|
Mohamedtaki Abdulaziz Tejani |
Research Funding - Bayer (Inst) |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; MSD; Nordic Bioscience; Pfizer; Roche |
Research Funding - GlaxoSmithKline; Novartis |
Travel, Accommodations, Expenses - Merck KGaA; Roche; Teva |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Taiho Pharmaceutical |
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Genentech; Lilly; Merck; Novartis; Pfizer; Taiho Pharmaceutical |
|
|
Speakers' Bureau - Daiichi Sankyo; Merck KGaA; Taiho Pharmaceutical; Takeda |
Research Funding - Otsuka |
|
|
No Relationships to Disclose |
|
|
Research Funding - Lilly (Inst); Roche (Inst); Taiho Pharmaceutical (Inst) |
Travel, Accommodations, Expenses - Celgene; Ipsen; Roche; SERVIER |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Amgen; Bayer; Daiichi Sankyo; Kyowa Hakko Kirin; MSD; Novartis; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda |
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst) |
|
|
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; BeiGene; Biocartis; Boehringer Ingelheim; Chugai Pharma; Foundation Medicine; Genentech; Genmab; HalioDx; Halozyme; Imugene; Inflection Biosciences; Ipsen; Kura Oncology; Lilly; Menarini; Merck Serono; Merrimack; Merus; Molecular Partners; MSD; Novartis; Peptomyc; Pfizer; Pharmacyclics; ProteoDesign; Rafael Pharmaceuticals; Roche; Roche; Sanofi; Seagen; Seagen; Servier; Symphogen; Taiho Pharmaceutical; VCN Biosciences |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly/ImClone; Merck; Pieris Pharmaceuticals; Roche/Genentech; Taiho Pharmaceutical |
|
|
|
Consulting or Advisory Role - Taiho Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Roche; SERVIER |
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst) |